Meet Our CEO

• Clinical Pharmacology
• Pharmacokinetics (PK)
• Pharmacodynamics (PD)
• Pharmacometrics (PM)
• Clinical Drug Development
• Clinical Trial Design
• Multiple Therapeutic Areas (Neurology, Oncology, Rare Genetic Disease, Cardiovascular, Autoimmune, Infectious Disease)
• Various drug molecule entities (Small Molecule, Monoclonal Antibody, Oligonucleotide, Peptide, Gene Therapy)

• Doctor of Philosophy (Ph.D.) in Pharmacokinetics, University of Witten-Herdecke, Germany 1994
• Doctor of Medicine (M.D.) in Clinical Medicine, Shanxi Medical University, China, 2018
• Master of Science (M.Sc.) in Pharmaceutical Chemistry & Molecular Modeling, Shanxi University, China 1988
• Bachelor of Science (B.Sc.) in Pharmaceutical Chemistry, Shanxi University, China, 1983

President and Chief Executive Officer (CEO)
XP Pharma Consulting, LLC, Stoneham, MA, 2019 - present

Senior Consultant- Clinical Pharmacology and Pharmacometrics
Nuventra Pharma Sciences, Inc., Cambridge, MA, 2019-2020

Senior Director- Clinical Pharmacology and Pharmacometrics
Alnylam Pharmaceuticals, Inc., Cambridge, MA. 2017-2019

Global Leader and Director - Clinical Pharmacology and Pharmacometrics
Alexion Pharmaceuticals, Inc., New Haven, CT, 2015-2017

Clinical Team Leader / Head of Clinical Pharmacology
Kyowa Hakko Kirin Pharma, Inc., Princeton, NJ, 2012-2015

Sr. Director/Head Clinical Pharmacology-Inflammation Hoffmann-La Roche, Inc., Nutley, NJ, 2001-2012

• 2 Shooting Star Awards for the successful launch of Onpattro (patisiran) in Canada and Japan (including submissions and responses to questions from FDA, EMEA and PDMA). Alnylam Pharmaceuticals, Inc., Cambridge, MA. 2019.
• Outstanding Scientific Contribution Award. The 21st SAPA-NE Scientific Symposium for Next generation of Gene and Cell Therapy. Oral Presentation: Onpattro (Patisiran): The First Approved RNAi Therapeutics. Nov 3, 2018. Boston, MA.
• Special Recognition for “Delivered tangible results, behaviors, and values, and future potential”. Alnylam Pharmaceuticals, Inc., Cambridge, MA. 2018.
• Steller Supernova Award for Passion for Excellence. Alnylam Pharmaceuticals, Inc., New. Cambridge, MA. 2017.Stellar All-Star Award for Sense of Urgency supporting Patisiran Filing Working Group, Alnylam Pharmaceuticals Inc., Cambridge, MA. 2017.
• Oscar Award for the best synopsis entitled “A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer” (ClinicalTrials.gov Identifier: NCT02987504). Alexion Pharmaceuticals Inc., New Haven, CT. March 2017.
• Alexion Innovator’s Award for scientific contribution to the treatment of a rare genetic disorder (mucopolysaccharidosis type IIIB) using enzyme replacement therapy. Alexion Pharmaceuticals, Inc., New Haven, CT. December 2016.
• Presidential Award for Outstanding Achievement in Significant Clarification and Clinical Understanding of Human Monoclonal anti-FGF23 Antibody (KRN23) in Treating Adults with X-Linked Hypophosphatemia. 2014 European Society of Paediatric Endocrinology Annual Meeting. Dublin, Ireland.
• Presidential Award for Innovative Clinical Research on human monoclonal anti-FGF23 antibody (KRN23) to patients with X-linked hypophosphatemia. Annual Meeting for American Society of Bone and Mineral Research. Baltimore, Maryland. 2013.
• Presidential Award for the Outstanding Poster and Abstract for development of Inverse Gaussian pharmacokinetics model for subcutaneous administration of enfuvirtide in treating HIV patients. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Washington DC, April 2-5, 2003.
• Pharmaceuticals Olympiad Gold Award for Innovation, Speed, and Growth Applied to the Team Approval of Enfuvirtide in EU and US, Hoffmann-La Roche, Inc., Nutley, NJ. 2003.
• First Prize for Best Student of Class 1983 at Shanxi University, Taiyuan, China.

• Oo, C., Zhang, X. Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better? Drug Discov Today. 2023 Aug;28(8):103674. https://www.sciencedirect.com/science/article/abs/pii/S1359644623001903?via%3Dihub
• Zhang, X., Goel, V., Robbie, J.G.  Pharmacokinetics of patisiran, the first approved RNA interference (RNAi) therapy, in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020;60(5):573–585. https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.1553
• Zhang, X., Goel, V., Attarwala, H. et al. Patisiran pharmacokinetics, pharmacodynamics, and exposure–response analyses in the phase 3 APOLLO trial, in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J Clin Pharmacol. 2020;60(1):37-49. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972979/pdf/JCPH-60-37.pdf
• Yamashita, T., Ueda, M.,…, Zhang, X., et al. Patisiran, an RNAi therapeutic for patients with hereditary transthyretin-mediated amyloidosis: Sub-analysis in Japanese patients from the APOLLO study. Neurol Clin Neurosci. 2020;8:251–260. https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.12396
• Judge, D. P., Kristen, A.V., …, Zhang, X., et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovas Drugs Ther. 2020;34(3):357-370. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242280/pdf/10557_2019_Article_6919.pdf
• Mahadevan, D., Lanasa, M.C., …, Zhang, X., et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: Blockade of the immune checkpoint CD200. J Immunother Cancer. 2019;7(1):227. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708181/pdf/40425_2019_Article_710.pdf
• Mukai, M., Uchimura, T., …, Zhang, X., et al. Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018;58(2): 193-201. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811788/pdf/JCPH-58-193.pdf
• Zhang, X., Peyret, T., Gosselin, N.H., et al. Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia. J Clin Pharmacol. 2016;56(4):429-348. https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.611
• Ruppe, M. D., Zhang, X., Imel, E.A., et al. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Reports. 2016;5:158–162. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926842/pdf/main.pdf
• Abdallah, H., Hsu, J.C., …, Zhang, X., et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from two randomized controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459-468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363244/pdf/JCPH-57-459.pdf
• Zhang, X., Chen, Y-C., and Terao, K. Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2017;10(5):471-482. https://www.tandfonline.com/doi/abs/10.1080/17512433.2017.1300058
• Sarantopoulos, J., Mita, M.M.,…, Zhang, X., et al. Phase 1 study of monotherapy with KHK2866, an anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibody, in patients with advanced cancer. Targeted Oncology. 2016;11:317-327. https://link.springer.com/article/10.1007/s11523-015-0394-5
• Duvic, M., Pinter-Brown,L.C., Zhang, X.,…, et al. Phase I/II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous or peripheral T-cell lymphoma. Blood. 2015;125(2):1883-1889. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375715/?report=printable
• Imel, E. A., Zhang, X., Ruppe, M.D., et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab. 2015;100(7):2565-2573. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495171/?report=printable
• Carpenter, T. O.,…, Zhang, X., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587-97. https://www.jci.org/articles/view/72829/pdf
• Zhang, X., Rowell, L., et al. Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis. Int J Clin Pharmacol Ther. 2014;52(1):27-38. https://pubmed.ncbi.nlm.nih.gov/24161161/
• Zhang, X., Imel, E. et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol.  2016;56(2):176-85. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042055/pdf/JCPH-56-176.pdf
• Zhang, X., Chen, Y-C., et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2013;51(8); 620-630. 2013. https://pubmed.ncbi.nlm.nih.gov/23782588/
• Zhang, X., Georgy, A., Rowell, L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther. 2013;51(6);443-455. https://pubmed.ncbi.nlm.nih.gov/23547848/
• Morcos, P., Zhang, X., McIntyre, C., et al. Pharmacokinetics, and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20 in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51(7); 537-548. https://pubmed.ncbi.nlm.nih.gov/23547849/
• Zhang, X., Morcos, P., et al. Clinical pharmacology of tocilizumab for the treatment of patients with systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6(2), 123–137. https://pubmed.ncbi.nlm.nih.gov/23473591/
• Zhang, X., Peck, R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol. 2011;4(5):539–558. https://www.tandfonline.com/doi/abs/10.1586/ecp.11.33
• Schmitt, C., Kuhn, B., Zhang, X., et al. Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2011;50(3):218-223. https://pubmed.ncbi.nlm.nih.gov/22373834/
• Schmitt, C., Kuhn, B., Zhang, X., et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735-740. https://ascpt.onlinelibrary.wiley.com/doi/10.1038/clpt.2011.35
• Grange, S., Schmitt, C., …,Zhang, X. Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin Pharmacol Ther. 2011;49(11):648-655. https://pubmed.ncbi.nlm.nih.gov/22011689/
• Zhang, X., Jordan, P., Cristea L.C. et al. Thorough QT/QTc study ebof ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. 2012;52(4):520-529. https://doi.org/10.1177/0091270011400071
• Zhang, X., Fettner, S., Zwanziger, E. et al. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother. 2011;55(2):680–687. https://journals.asm.org/doi/10.1128/AAC.00992-10
• Zhang, X., Fettner, S., Winter, E. et al. Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. Int. J Clin Pharmacol Ther, 2011;49(6): 345-352. https://pubmed.ncbi.nlm.nih.gov/21612741/
• Zhang, X., Huang, Y., Navarro, M.T., et al. A Proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis. J. Clin Pharmacol. 2010;50(9):1031-1038. https://accp1.onlinelibrary.wiley.com/doi/10.1177/0091270009357433
• Zhang, X., Silkey, M., Schumacher, M., et al. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. J Clin Pharmacol. 2009;49(5):534-539. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/0091270008330158
• Jamois, C., Smith, P., …, Zhang, X.. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addiction Biology. 2009;14(3):321-327. https://onlinelibrary.wiley.com/doi/10.1111/j.1369-1600.2009.00158.x
• Kaeser, K., Zandt, H., …, Zhang, X. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother. 2009;53(2):609–614. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630604/pdf/0769-08.pdf
• Zhang, X., Lin, T., Bertasso, A., et al. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. J Clin Pharmacol. 2007;47(4):510-517. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/0091270006299089
• Patel, I. H., Zhang, X., et al. Pharmacokinetics, pharmacodynamics and drug Interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-186. https://pubmed.ncbi.nlm.nih.gov/15656696/
• Mould, D. R., Zhang, X., Nieforth, K., et al. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2005;77(6):515-528. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.02.005
• Ruxrungtham, K., Boyd, M.,…, Zhang, X., et al. Lack of Interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol. 2004;44(7):793-803. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/0091270004266489
• Zhang, X., Lalezari, J. P., et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2004;75(6):558-568. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2004.02.003
• Boyd, M. A., Zhang, X., et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol. 2003;43(12):1382-1391.
• Lalezari, J. P, Patel, I. H., Zhang, X., Dorr, A. et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol. 2003;28(2):217-22. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/0091270003259220
• Zhang, X., Nieforth, K.,Lang, J.M., et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with immunodeficiency virus: Inverse Gaussian Density absorption and 2-compartment disposition. Clin Pharmacol Ther. 2002;72(1):10-19. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2002.125945
• Zhang, Z., Mehvar, R. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: plasma and tissue disposition. J Pharm Sci. 2001; 90(12):2078-2087. https://pubmed.ncbi.nlm.nih.gov/11745766/
• Zhang, Z., Mehvar, R. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. Int J Pharm. 2001; 229(1-2):173-82. https://pubmed.ncbi.nlm.nih.gov/11604270/
• Mehvar, R., Zhang, Z. Development and application of an isolated perfused rat liver model to study the stimulation and inhibition of tumor necrosis factor-alpha production ex vivo. Pharm Res.  2002;19(1):47-53. https://pubmed.ncbi.nlm.nih.gov/11837700/

• Zhang, X., Terao, K., Jahreis, A. M., Bao, M. Subcutaneously Administered Anti-IL-6 Receptor Antibody. Assigned to Hoffmann-La Roche Inc, Genentech Inc., and Chugai Seiyaku Kabushiki Kaisha. Pub. No.: US 2021/0228597 A1. Pub. Date: Jul. 29, 2021.
• Zhang, X., Terao, K. Subcutaneously Administered Anti-IL-6 Receptor Antibody. Assigned to Hoffmann-La Roche Inc and Chugai Seiyaku Kabushiki Kaisha. Patent No.: US 10,874,677 B2 Date of Patent: Dec. 29, 2020.
• Zhang, X., Terao, K., Harari, O. A. Subcutaneously Administered Anti-IL-6 Receptor Antibody for treatment of Juvenile idiopathic Arthritis. Assigned to Hoffmann-La Roche Inc and Chugai Seiyaku Kabushiki Kaisha. Patent No. US 10,231,981 B2. Date of Patent: Mar. 19, 2019.
• Zhang, X., Pan, W. J. “Method of Treating Acute Myeloid Leukemia (AML) with combinations of anti-CD200 antibodies, cytarabine, and daunorubicin”. International Publication No.: WO 2018/075 408 A1. International Publication Date: 26 April 2018.
• Zhang, X., Pan, W. J. “Method of Treating Solid tumor with anti-CD200 antibodies”. Assigned to Alexion Pharmaceuticals Inc. International Publication No.: WO 2018/102594 A1. International Publication Date: 07 June 2018.
• Zhang, X., Terao, K, Harari, O. A. Subcutaneously Administered Anti-IL-6 Receptor Antibody for treatment of Juvenile idiopathic Arthritis. Assigned to Hoffmann-La Roche Inc and Chugai Seiyaku Kabushiki Kaisha. Patent No.: US 9,750,752 B2. Date of Patent: Sept 5, 2017.
• Zhang, X., Terao, K., Jahreis, A. Subcutaneously Administered Anti-IL-6 Receptor Antibody for treatment of Systemic Sclerosis. Assigned to Hoffmann-La Roche Inc., Genentech Inc., and Chugai Seiyaku Kabushiki Kaisha. Patent No. US 9,539,263 B2. Date of patent: Jan. 10, 2017
• Zhang, X., Terao, K., Harari, O. A. Subcutaneously Administered Anti-IL-6 Receptor Antibody. Assigned to Hoffmann-La Roche Inc and Chugai Pharmaceutical Inc. Pub. No.: US 2014/0056883 A1. Pub. Date: Feb. 27, 2014
• Zhang, X., Bao, M., Jahres, M. A, Terao K. US Patent. “Subcutaneously Administered Anti-IL-6 Receptor Antibody. Assigned to Hoffmann-La Roche Inc, Genentech Inc. Patent No. 8,580,264 B2. Nov 12, 2013.